SEC Company Response from Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Jun 30, 2017
Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: June 30, 2017 · CIK: 0001130166 · Accession: 0001571049-17-006445
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218305
Referenced dates: June 9, 2017
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance Re: Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 26, 2017 File No. 333-218305
Dear Ms. Hayes:
We are submitting this letter on behalf of Cyclacel Pharmaceuticals, Inc. (the “Company”) in response to comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) received by letter dated June 9, 2017 (the “Comment Letter”) from the Division of Corporate Finance and Office of Healthcare and Insurance, to Spiro Rombotis, the Company’s Chief Executive Officer, relating to the above-referenced registration statement on Form S-1 of the Company filed with the Commission on May 26, 2017 (the “Registration Statement”).
For convenient reference, we have set forth below in italics the Staff’s comment set forth in the Comment Letter and have keyed the Company’s response to the numbering of the comment and the heading used in the Comment Letter. This letter is being filed with the Commission with Amendment No. 1 to the Registration Statement (the “Amended Registration Statement”). Any capitalized terms used herein, but not defined shall have the meanings ascribed to them in the Amended Registration Statement. The response is based on information provided to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. by representatives of the Company. Page numbers referred to in this response reference the applicable pages of the Amended Registration Statement.
Facing Page
1. Please revise the fee table to calculate the registration fee based on each of the securities being offered. Please refer to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations for guidance.
Response: In response to the Staff’s comment, the Company has revised the fee table in the Amended Registration Statement accordingly.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Boston | London | Los Angeles | New York | San Diego | San Francisco | Stamford | Washington
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
United States Securities and Exchange Commission
June 30, 2017
Page 2
Cover Page
2. Please tell us whether you will use the recent stock price listed on the cover page to determine the offering price of the units. If you will not use the recent stock price to set the offering price, then please include disclosure on the cover page indicating the factors that will be used to determine the offering price.
Response: The Company respectfully acknowledges the Staff’s comment. In response to the Staff’s comment, the Company has clarified on the cover of the Amended Registration Statement that the recent price of its common stock will be one of several factors in determining the public offering price. Other factors to be considered in determining the public offering price include the Company’s history, prospects, the industry in which it operates, the previous experience of its executive officers and the general condition of the securities markets at the time of this offering.
Incorporation of Information by Reference, page 60
3. Please incorporate by reference your definitive proxy statement filed April 12, 2017. Please refer to Item 12(a)(2) of Form S-1 for guidance.
Response: In response to the Staff’s comment, the Company has incorporated its definitive proxy statement by reference in the Amended Registration Statement.
* * * * *
We hope that the above response will be acceptable to the Staff. Please do not hesitate to contact me at 212-692-6774 or jipapernik@mintz.com with any comments or questions regarding the Amended Registration Statement and this letter. We thank you for your time and attention.
Sincerely,
/s/ Joel I. Papernik
Show Raw Text
CORRESP
1
filename1.htm
Joel I. Papernik | 212 692 6774 | jipapernik@mintz.com
Chrysler Center
666 Third Avenue
New York, NY 10017
212-935-3000
212-983-3115 fax
www.mintz.com
June 30, 2017
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance
Re: Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed May 26, 2017
File No. 333-218305
Dear Ms. Hayes:
We are submitting this letter on
behalf of Cyclacel Pharmaceuticals, Inc. (the “Company”) in response to comments from the staff (the “Staff”)
of the Securities and Exchange Commission (the “Commission”) received by letter dated June 9, 2017 (the “Comment
Letter”) from the Division of Corporate Finance and Office of Healthcare and Insurance, to Spiro Rombotis, the Company’s
Chief Executive Officer, relating to the above-referenced registration statement on Form S-1 of the Company filed with the Commission
on May 26, 2017 (the “Registration Statement”).
For convenient reference, we have
set forth below in italics the Staff’s comment set forth in the Comment Letter and have keyed the Company’s response
to the numbering of the comment and the heading used in the Comment Letter. This letter is being filed with the Commission with
Amendment No. 1 to the Registration Statement (the “Amended Registration Statement”). Any capitalized terms
used herein, but not defined shall have the meanings ascribed to them in the Amended Registration Statement. The response is based
on information provided to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. by representatives of the Company. Page numbers
referred to in this response reference the applicable pages of the Amended Registration Statement.
Facing Page
1. Please revise the fee table to calculate the registration fee based on each of the securities being offered. Please refer
to Question 240.06 of the Securities Act Rules Compliance and Disclosure Interpretations for guidance.
Response: In response to the Staff’s comment, the
Company has revised the fee table in the Amended Registration Statement accordingly.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Boston | London | Los
Angeles | New York | San Diego | San Francisco | Stamford | Washington
Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.
United States Securities and Exchange Commission
June 30, 2017
Page 2
Cover Page
2. Please tell us whether you will use the recent stock price listed on the cover page to determine the offering price of the
units. If you will not use the recent stock price to set the offering price, then please include disclosure on the cover page indicating
the factors that will be used to determine the offering price.
Response: The Company respectfully acknowledges the Staff’s
comment. In response to the Staff’s comment, the Company has clarified on the cover of the Amended Registration Statement
that the recent price of its common stock will be one of several factors in determining the public offering price. Other
factors to be considered in determining the public offering price include the Company’s history, prospects, the industry
in which it operates, the previous experience of its executive officers and the general condition of the securities markets at
the time of this offering.
Incorporation of Information by Reference, page 60
3. Please incorporate by reference your definitive proxy statement filed April 12, 2017. Please refer to Item 12(a)(2) of Form
S-1 for guidance.
Response: In response to the Staff’s comment, the
Company has incorporated its definitive proxy statement by reference in the Amended Registration Statement.
* * * * *
We hope that the above response will be acceptable to
the Staff. Please do not hesitate to contact me at 212-692-6774 or jipapernik@mintz.com with any comments or questions regarding
the Amended Registration Statement and this letter. We thank you for your time and attention.
Sincerely,
/s/ Joel I. Papernik
Joel I. Papernik
cc: Securities and Exchange Commission
Suzanne Hayes
Johnny Gharib
Erin Jaskot
Cyclacel Pharmaceuticals, Inc.
Spiro Rombotis, Chief Executive Officer